Denali Therapeutics Inc (NASDAQ:DNLI) Insider Carole Ho Sells 17,500 Shares

Share on StockTwits

Denali Therapeutics Inc (NASDAQ:DNLI) insider Carole Ho sold 17,500 shares of the firm’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $18.78, for a total transaction of $328,650.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Carole Ho also recently made the following trade(s):

  • On Friday, May 10th, Carole Ho sold 17,500 shares of Denali Therapeutics stock. The stock was sold at an average price of $22.85, for a total transaction of $399,875.00.
  • On Thursday, March 14th, Carole Ho sold 1,000 shares of Denali Therapeutics stock. The stock was sold at an average price of $25.01, for a total transaction of $25,010.00.

Denali Therapeutics stock traded up $0.12 during trading hours on Wednesday, reaching $19.03. 205,116 shares of the stock were exchanged, compared to its average volume of 378,160. The company has a market capitalization of $1.81 billion, a price-to-earnings ratio of -48.79 and a beta of 2.28. The company has a quick ratio of 11.55, a current ratio of 11.55 and a debt-to-equity ratio of 0.14. Denali Therapeutics Inc has a twelve month low of $12.32 and a twelve month high of $28.86.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). The firm had revenue of $4.21 million for the quarter, compared to analyst estimates of $12.88 million. Denali Therapeutics had a negative return on equity of 10.23% and a negative net margin of 38.84%. On average, sell-side analysts expect that Denali Therapeutics Inc will post -1.48 earnings per share for the current year.

A number of equities analysts recently commented on the stock. ValuEngine lowered shares of Denali Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, May 28th. Zacks Investment Research lowered shares of Denali Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, May 2nd.

A number of institutional investors have recently made changes to their positions in the business. TD Asset Management Inc. grew its stake in Denali Therapeutics by 2.2% during the first quarter. TD Asset Management Inc. now owns 23,400 shares of the company’s stock worth $543,000 after buying an additional 500 shares in the last quarter. Principal Financial Group Inc. grew its stake in Denali Therapeutics by 0.4% during the first quarter. Principal Financial Group Inc. now owns 186,760 shares of the company’s stock worth $4,337,000 after buying an additional 810 shares in the last quarter. BlueMountain Capital Management LLC acquired a new stake in Denali Therapeutics during the first quarter worth about $26,000. Legal & General Group Plc grew its stake in Denali Therapeutics by 16.3% during the fourth quarter. Legal & General Group Plc now owns 8,638 shares of the company’s stock worth $179,000 after buying an additional 1,212 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Denali Therapeutics by 13.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,436 shares of the company’s stock worth $216,000 after buying an additional 1,237 shares in the last quarter. Hedge funds and other institutional investors own 71.69% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/4369616/denali-therapeutics-inc-nasdaqdnli-insider-carole-ho-sells-17500-shares.html.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

Read More: Trading on Margin

Insider Buying and Selling by Quarter for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Denali Therapeutics Inc  Insider Carole Ho Sells 17,500 Shares
Denali Therapeutics Inc Insider Carole Ho Sells 17,500 Shares
StarterCoin Market Cap Hits $308,930.00
StarterCoin Market Cap Hits $308,930.00
Uniqure  Stock Price Up 6%
Uniqure Stock Price Up 6%
TCF Financial Co.  EVP Sells 40,000 Shares
TCF Financial Co. EVP Sells 40,000 Shares
Restoration Hardware Holdings, Inc  Expected to Post Earnings of $1.54 Per Share
Restoration Hardware Holdings, Inc Expected to Post Earnings of $1.54 Per Share
Unification  Market Capitalization Achieves $1.61 Million
Unification Market Capitalization Achieves $1.61 Million


© 2006-2019 Ticker Report